Purpose: S-1 is an oral fluoropyrimidine. The purpose of this study was to review the clinical outcomes of S-1 with concurrent radiotherapy for patients with oropharyngeal cancer. Materials and Methods: Between 2002 and 2007, 38 patients with oropharyngeal cancer treated concurrently with S-1 and definitive radiotherapy were reviewed. The clinical stage was Stage I in 4 patients, Stage II in 7, Stage III in 7, and Stage IV in 20. S-1 was administered orally twice daily for 4 consecutive weeks followed by a 2-week drug withdrawal. The initial dose of S-1 was 65 mg/m 2 /day. All patients were treated using three-dimensional conformal radiotherapy with a median total dose of 65.1 Gy (range, 60.0-71.0 Gy). Clinical outcomes and major acute toxicities were analyzed based on medical records and clinical followup. Results: With a median follow-up time of 33 months, the 3-year estimates of local-regional control, distant metastases-free survival, disease-free survival, and overall survival for all patients were 75%, 80%, 65%, and 80%, respectively. The 3-year estimates of local-regional control according to stage were 100% for Stages I and II, 86% for Stage III, and 56% for Stage IV. The rate of ≥ Grade 3 acute mucositis was 32%, and the rate of ≥ Grade 3 hematological toxicities was 8%. No other severe toxicities were observed. Conclusions: Concurrent chemoradiotherapy with S-1 was found to be effective, especially for early disease. The treatment-related toxicities were acceptable, and the incidence of myelotoxicity was low. Further study must be carried out to compare with other chemotherapy regimens.
INTRODUCTION
The treatment of oropharyngeal cancer has traditionally been surgery alone, radiotherapy alone, or a combination of both. There is little evidence to suggest that either primary surgery or radiotherapy is superior in terms of disease control or survival. Radiotherapy is preferred at many institutions because of the presumed lower morbidity and better functional and cosmetic outcomes compared with surgical treatment. 1) Recently, many randomized trials have shown that chemoradiotherapy (CRT) improves locoregional control and survival in treating locally advanced head and neck cancer. [2] [3] [4] [5] [6] [7] In the 2006 German meta-analysis of 32 trials, 5-fluorouracil (5-FU) as a single drug and cisplatin as a single drug or in combination with 5-FU was found to exhibit the largest benefit. 8) At our institution, patients with cancer of the oropharynx have been initially treated with concurrent CRT to preserve organ function as much as possible. At a radiation dose of 40-45 Gy, the primary disease is evaluated clinically and/or by imaging. If complete response is achieved at the primary site, CRT is continued with neck dissection planned for residual neck disease after completion of CRT. If persistent primary disease is obvious, surgery is performed. The chemotherapy regimen used in the CRT has generally utilized 5-fluorouracil (5-FU) as a single agent. CRT with 5-FU has been shown to provide better therapeutic results than radiotherapy alone. 9) We have developed a combination therapy including 5-FU, vitamin A, and radiotherapy (FAR therapy) for head and neck cancer, and the effectiveness of the FAR therapy has been reported. [10] [11] [12] S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) is a novel oral fluoropyrimidine that combines tegafur, a metabolically activated prodrug of 5-fluorouracil (5-FU), with 5-chloro-2, 4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo). 13) CDHP enhances the pharmacological actions of 5-FU by potently inhibiting its degradation, and Oxo reduces the incidence of gastrointestinal toxicities by suppressing the activation of 5-FU in the gastrointestinal tract. In a pharmacokinetic study of S-1, plasma 5-FU concentrations were shown to be almost equivalent to those obtained with continuous venous infusion of 5-FU. 14) In the late phase II trials in patients with advanced or recurrent head and neck cancer in Japan, 15) S-1 alone showed an overall response rate of 28.8% and a response rate at the primary lesion of 48.1%. In addition to the high response rates, the incidences of adverse effects were shown to be low. In the late Phase II clinical trials of S-1 alone in 449 patients, the incidences of ≥ Grade 3 adverse reactions were less than 10%, except for neutropenia (11.1%). 16) These data led us to use S-1 concurrently with radiotherapy instead of 5-FU for patients with head and neck cancer.
The purpose of this study was to present the Kyushu University Hospital experience with concurrent CRT with S-1 in treating oropharyngeal cancer and to compare our findings with previous literature on this topic.
MATERIALS AND METHODS
Between 2002 and 2007, 45 patients with newly diagnosed oropharyngeal cancer without distant metastases were started on concurrent CRT with S-1 at the Kyushu University Hospital. After a radiation dose of 40-45 Gy, when an evaluation of the primary disease was performed, 7 of these 45 patients underwent surgery because of residual tumor at the primary site. Thirty-seven patients with complete response and one with unresectable residual tumor at the primary site continued CRT to a total dose of ≥ 60 Gy. These 38 patients who received definitive radiotherapy with S-1 were included in the present analysis.
The patient characteristics are shown in Table 1 . Thirtyfour (89%) of the patients were men, and the median age was 61 years (range, 37-82 years). Thirty-six patients (95%) had squamous cell histology. The primary sites were the lateral wall in 26 patients, the superior wall in 6, the posterior wall in 4, and the anterior wall in 2. Twenty-eight patients had a T1-2 primary and 10 patients had a T3-4 primary. S-1 was administered orally twice daily for 3 or 4 consecutive weeks followed by a 2-week drug withdrawal from the beginning to the end of radiotherapy. The initial dose of S-1 was 65 mg/m 2 according to a phase I study of concurrent radiotherapy with S-1; 17) patients with a body surface area (BSA) of more than 1.5 m 2 received 100 mg daily, those with a BSA of 1.25 m 2 or more but less than 1.5 m 2 received 80 mg daily, and those with a BSA of less than 1.25 m 2 received 50 mg daily. If patients had renal dysfunction, their initial daily dose was reduced from 100 mg to 80 mg or from 80 mg to 50 mg according to the level of creatinine clearance. If patients developed toxicities, their daily dose was reduced or S-1 administration was discontinued on the physicians' recommendation. The initial dose of S-1 was 120 mg in one patient, 100 mg in 20 patients, 80 mg in 16 patients, and 60 mg in one patient. All patients received external beam radiotherapy. Threedimensional conformal radiotherapy was delivered through a linear accelerator with a 4 MV X-ray. Conventional fractionation was used with a daily dose of 1.8-2.0 Gy, 5 times per week. Initial radiation fields generally encompassed the primary tumor, the bilateral neck, and the supraclavicular fossae. Lateral two fields with or without a single anterior field were used. After the dose of 40-45 Gy, the primary lesion and the lymphadenopathy were boosted with reduced field to a total dose of 60-70 Gy.
The overall survival, local control rate, regional control rate, local-regional control rate, and rate of distant metastases were calculated using the Kaplan-Meier method. The survival and local-regional control rates were calculated from the first day of radiotherapy to the date of the event. The statistical significance of differences between the survival curves was assessed with the log-rank test. A p value less than 0.05 was considered to be significant. Acute and late toxicity was assessed using the Common Terminology Criteria for Adverse Events, version 3.0.
RESULTS

Treatment outcomes
All patients completed the scheduled radiotherapy course. The radiotherapy ranged from 60.0 to 71.0 Gy (median, 65.1 Gy). Thirty-four patients (89%) had a treatment break longer than 3 days to allow for evaluation of the primary disease at a dose of 40-45 Gy and/or due to acute mucositis. The median treatment time of radiotherapy was 9.1 weeks (range, 6.0-12.0 weeks). The administration of S-1 was discontinued in 2 patients, with one showing elevated serum creatine values and the other developing nausea. The dose of S-1 was reduced during treatment in 2 patients due to Grade 2 thrombocytopenia. Neck dissection was performed within 3 months of the completion of treatment in 10 of the 12 patients who had suspected persistent disease in the neck, as assessed clinically or by imaging. However, only one of these 10 patients had pathologically viable carcinoma cells.
The median follow-up time was 33 months (range, 3.4-78.3 months). Of the 38 patients, 17 patients with early disease (T1-2 and N0-1) had no locoregional recurrences. Of the remaining 21 patients with advanced disease (T1-2 and N2-3 or T3-4 and any N), 8 (33%) developed locoregional recurrences. The characteristics of these patients with local and regional failures are summarized in Table 2 . There was one isolated local recurrence at the primary site at the 7-month follow-up. Three patients developed recurrences at the primary site and the neck at 4, 7, and 15 months after treatment. Four additional patients developed nodal recurrences. Two of the 8 patients with locoregional failure underwent surgery, and successful salvage was achieved. At the last contact, 5 of the 8 patients with locoregional failure had died of disease, 2 who had undergone surgery were alive without disease, and one patient who had received chemotherapy was alive with disease.
Distant metastases developed in one of the 17 patients with early disease, and in 5 of the 21 patients with advanced disease. Four of these 6 patients with distant failure had disease control above the clavicles. The site of distant metastases was the lung in 4 patients, the bone in one patient, and the mediastinal lymph node in one patient. At the last contact, 2 of the 4 patients with distant metastases and locoregional control had died of disease, one with mediastinal lymph node metastasis who had received chemoradiotherapy was alive without disease, and one who had received chemotherapy was alive with disease.
The 3-year rates of local-regional control by disease stage were as follows: Stage I, 100%; Stage II, 100%; Stage III, 86%; Stage IV, 56%; and overall, 75% (Fig. 1) . The 3-year rates of ultimate local-regional control, including patients successfully treated with salvage therapy after a localregional recurrence, were as follows: I, 100%; II, 100%; III, 86%; IV, 71%; and overall, 83%. T-stage (T1-2 vs. T3-4) and N-stage (N0-1 vs. N2-3) were significantly associated with local-regional control in the univariate analysis. The 3-year local-regional control rate for patients with T1-2 disease was 87% compared with 37% for patients with T3-4 disease (p = 0.0026) (Fig. 2) . The 3-year local-regional control rate for patients with N0-1 disease was 94% compared with 56% for patients with N2-3 disease (p = 0.0197) (Fig. 3) . Overall treatment time (< 9.0 weeks vs. ≥ 9.0 weeks, p = 0.2480) and total radiation dose (< 65. (Fig. 4) .
Acute and late toxicity
The acute toxicity of chemoradiotherapy by site and grade is detailed in Table 3 . The incidence of acute mucositis higher than Grade 2 was 31%. Four of the 38 patients (11%) needed either a nasogastric feeding tube or total parenchymal nutrition during treatment. The rate of Grade 3 leukopenia was only 5.2%. No other severe acute toxicities were observed.
Late complications were scored according to the Radiation 
DISCUSSION
Radiotherapy and chemotherapy play an important role in treating oropharyngeal cancer. These two modalities may be given concurrently or sequentially. Previously reported randomized trials and meta-analyses have demonstrated that concomitant chemoradiotherapy significantly improves survival and locoregional control compared with radiotherapy alone in the treatment of advanced head and neck cancer. Radiotherapy with concurrent chemotherapy is considered to be the standard treatment for advanced oropharyngeal cancer when nonsurgical treatment is planned. Radiotherapy alone, however, is favored for the treatment of early-stage oropharyngeal cancer because treatment outcomes with radiotherapy alone are not compromised. The National Comprehensive Cancer Network guidelines (2008) recommend definitive radiotherapy or surgery for early oropharyngeal cancer (T1-2 and N0-1).
Platinum-based regimens are most widely used in the concurrent settings, although various chemotherapy regimens have been used. A systematic review published in 2000 by Browman et al. included stratification for the use of a platinum agent as well as for combination chemotherapy or no combination therapy.
3) Platinum-based regimens were the only ones resulting in a statistically significant difference when used either alone or in combination. In the MACH-NC meta-analysis, the effects of chemotherapy were significantly higher with platinum than with other agents when used as single-agent chemotherapy, although no significant difference was seen between platinum-based regimens and other regimens in multi-agent chemotherapy. 18) In the recent German meta-analysis, 5-FU as a single drug and cisplatin as a single drug or in combination with 5-FU exhibited the largest benefit. 8) However, these platinum-based regimens have substantial toxicities and are not suitable for all patients.
S-1 is an oral fluoropyrimidine developed to improve the tumor-selective cytotoxicity of 5-FU and reduces gastrointestinal toxicity through the addition of two modulators, CDHP and Oxo.
13) S-1 shows antitumor activity in head and neck cancer when used in monotherapy for advanced or recurrent disease, with an overall response rate of 28.8%. 15) In addition, the incidence of adverse reactions of Grade 2 or more is low (1.7-25.4%). S-1 also has a radiosensitizing effect, which has been shown in preclinical trials of a human oral cancer cell lines, human oral cancer xenografts, and human colon cancer xenografts. [20] [21] [22] Moreover, some clinical trials have recently shown the efficacy of S-1 and concurrent radiotherapy for head and neck cancer. [23] [24] [25] [26] In the present study, the 3-year overall survival and locoregional control were 100% for Stage I-II. The localregional control rates achieved with radiotherapy alone for Stage I-II disease were 73-100% in previous studies. [27] [28] [29] [30] One of these studies was an institutional review that included 176 patients with Stage I-II oropharyngeal cancer reported by Selek et al. 27) They reported that the T-stage classification was associated with local-regional control. The 5-year localregional control rate for patients with T1-Tx disease was 90% compared with 77% for patients with T2 disease. In this study, the local-regional control rate for T2 disease was 100% as well as that for T1 disease in patients with Stage I-II. Concurrent CRT with S-1 for early-disease oropharyngeal cancer compared favorably with radiotherapy alone, especially for Stage II disease.
The 3-year overall survival rate for Stage III-IV disease was 71% and the local-regional control rate was 65% in this study. These rates are comparable to those observed in the GORTEC 94-02 study in which conventional fractionated radiation was given with concomitant chemotherapy using three cycles of carboplatin and 5-FU. 31) In the GORTEC 94-01 study, the 3-year overall survival was 51% and the 3-year locoregional control rate was 66%. The rate of local failure in this study was lower than that achieved in the GORTEC study. Four patients (15% of the patients with Stage III-IV disease) developed local relapse in our study, whereas 33% experienced local recurrence in the GORTEC study. However, these relatively good outcomes achieved with CRT with S-1 in the present study could be because the 7 patients who received surgery after a dose of 40-45 Gy due to residual primary tumors were excluded for the analysis. In addition, some of the patients lacked a long follow-up time. Therefore, further study will be needed in order to confirm the effectiveness of concurrent CRT with S-1 for the oropharyngeal cancer.
In terms of compliance with concurrent CRT with S-1, all patients completed the planned radiotherapy. The rate of higher than Grade 2 mucositis was 31%, and no hematological toxicities and dermatitis of higher than Grade 2 were observed. No severe late complications except for xerostomia were seen. Concurrent use of S-1 with radiotherapy was considered to be tolerable. However, the duration of radiotherapy was prolonged, with a median treatment break of 13 days. There were two main reasons for this treatment break. One is that it was necessary to evaluate primary disease at a dose of 40-45 Gy to determine whether the radiotherapy should be continued, and the other was the presence of acute mucositis. Most of patients who Percutanenous endoscopic gastrostomy (PEG) has not been performed at our institution thus far. The prolongation of the overall treatment time in radiotherapy has been shown to be related to a decreased local control rate in the treatment of head and neck cancer. [32] [33] [34] [35] In the German meta-analysis, smaller survival benefits were observed in studies with a prolonged overall treatment time in chemoradiotherapy. 8) Although the treatment outcomes in our study were comparable to those reported previously, as described above, efforts must be rigorous in giving nutrition support such as PEG, recommendations for oral and dental hygiene, and controlling pain during radiotherapy in order to prevent treatment-related interruptions.
In conclusion, we observed 100% 3-year locoregional control for Stage I-II disease and 65% control for Stage III-IV disease with concurrent chemoradiotherapy with S-1. This regimen was found to be effective, especially for earlystage oropharyngeal cancer. The rate of hematological toxicity was lower than that obtained with platinum-based regimens. The acute mucositis was a limiting factor. Further studies are needed to define the optimal schedules of radiotherapy with S-1 and to compare the outcomes of S-1 to platinum-based regimens. We have started a randomized trial of CDDP versus S-1 in chemoradiotherapy for head and neck cancer.
